摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2,6-Dichlorophenylamino)-6,6-dimethyl-7-hydroxy-7,8-dihydro-1H,6H-imidazo[4,5-h]isoquinoline-9-one | 333458-25-6

中文名称
——
中文别名
——
英文名称
2-(2,6-Dichlorophenylamino)-6,6-dimethyl-7-hydroxy-7,8-dihydro-1H,6H-imidazo[4,5-h]isoquinoline-9-one
英文别名
2-(2,6-dichloroanilino)-7-hydroxy-6,6-dimethyl-7,8-dihydro-3H-imidazo[4,5-h]isoquinolin-9-one
2-(2,6-Dichlorophenylamino)-6,6-dimethyl-7-hydroxy-7,8-dihydro-1H,6H-imidazo[4,5-h]isoquinoline-9-one化学式
CAS
333458-25-6
化学式
C18H16Cl2N4O2
mdl
——
分子量
391.257
InChiKey
QFGYXIMGXUNKMT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.505±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    90
  • 氢给体数:
    4
  • 氢受体数:
    4

SDS

SDS:934a8d8512d34bfedd531210dd514e1b
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(2,6-Dichlorophenylamino)-6,6-dimethyl-7-hydroxy-7,8-dihydro-1H,6H-imidazo[4,5-h]isoquinoline-9-one 在 sodium tetrahydroborate 、 三氟乙酸 作用下, 反应 4.0h, 以92%的产率得到2-(2,6-Dichloro-phenylamino)-6,6-dimethyl-1,6,7,8-tetrahydro-imidazo[4,5-h]isoquinolin-9-one
    参考文献:
    名称:
    Discovery of 2-Phenylamino-imidazo[4,5-h]isoquinolin-9-ones:  A New Class of Inhibitors of Lck Kinase
    摘要:
    An imidazo[4,5-h]isoquinolin-7,9-dione (1) was identified as an adenosine 5'-triphosphate competitive inhibitor of lck by high throughput screening. Initial structure-activity relationship studies identified the dichlorophenyl ring and the imide NH as important pharmacophores. A binding model was constructed to understand how 1 binds to a related kinase, lick. These results suggested that removing the gem-dimethyl group and flattening the ring would enhance activity. This was realized by converting 1 to the imidazo[4,5-h]isoquinolin-9-one (20), resulting in an 18-fold improvement in potency against lck and a 50-fold increase in potency in a cellular assay.
    DOI:
    10.1021/jm020113o
  • 作为产物:
    描述:
    参考文献:
    名称:
    Discovery of 2-Phenylamino-imidazo[4,5-h]isoquinolin-9-ones:  A New Class of Inhibitors of Lck Kinase
    摘要:
    An imidazo[4,5-h]isoquinolin-7,9-dione (1) was identified as an adenosine 5'-triphosphate competitive inhibitor of lck by high throughput screening. Initial structure-activity relationship studies identified the dichlorophenyl ring and the imide NH as important pharmacophores. A binding model was constructed to understand how 1 binds to a related kinase, lick. These results suggested that removing the gem-dimethyl group and flattening the ring would enhance activity. This was realized by converting 1 to the imidazo[4,5-h]isoquinolin-9-one (20), resulting in an 18-fold improvement in potency against lck and a 50-fold increase in potency in a cellular assay.
    DOI:
    10.1021/jm020113o
点击查看最新优质反应信息

文献信息

  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    申请人:——
    公开号:US20020016460A1
    公开(公告)日:2002-02-07
    Disclosed are novel compounds of formula (I): 1 wherein Ar 1 , R a , R 4 , R 5 , X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).
    揭示了式(I)的新化合物:其中Ar1、Ra、R4、R5、X和Y的定义如下,这些化合物可用作某些蛋白酪氨酸激酶的抑制剂,因此可用于治疗与这些激酶相关的疾病,例如由于细胞不当增殖而导致的疾病,包括自身免疫疾病、慢性炎症性疾病、过敏疾病、移植排斥和癌症,以及由脑缺血引起的疾病,如中风。还披露了制备这些化合物的方法,这些方法中有用的新中间体以及包含式(I)化合物的组合物。
  • HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES
    申请人:BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
    公开号:EP1222187B1
    公开(公告)日:2004-09-22
  • US6506769B2
    申请人:——
    公开号:US6506769B2
    公开(公告)日:2003-01-14
  • US6770639B2
    申请人:——
    公开号:US6770639B2
    公开(公告)日:2004-08-03
  • Discovery of 2-Phenylamino-imidazo[4,5-<i>h</i>]isoquinolin-9-ones:  A New Class of Inhibitors of Lck Kinase
    作者:Roger J. Snow、Mario G. Cardozo、Tina M. Morwick、Carl A. Busacca、Yong Dong、Robert J. Eckner、Stephen Jacober、Scott Jakes、Suresh Kapadia、Susan Lukas、Maret Panzenbeck、Gregory W. Peet、Jeffrey D. Peterson、Anthony S. Prokopowicz、Rosemarie Sellati、Robert M. Tolbert、Matt A. Tschantz、Neil Moss
    DOI:10.1021/jm020113o
    日期:2002.8.1
    An imidazo[4,5-h]isoquinolin-7,9-dione (1) was identified as an adenosine 5'-triphosphate competitive inhibitor of lck by high throughput screening. Initial structure-activity relationship studies identified the dichlorophenyl ring and the imide NH as important pharmacophores. A binding model was constructed to understand how 1 binds to a related kinase, lick. These results suggested that removing the gem-dimethyl group and flattening the ring would enhance activity. This was realized by converting 1 to the imidazo[4,5-h]isoquinolin-9-one (20), resulting in an 18-fold improvement in potency against lck and a 50-fold increase in potency in a cellular assay.
查看更多